Medytox has expanded its damages claim against Daewoong Pharmaceutical tenfold to ₩500 billion in an ongoing intellectual property dispute over botulinum toxin formulation and manufacturing. The escalation signals Medytox's confidence in its legal position and reflects the high stakes of toxin market share in South Korea, where both companies compete for domestic and export revenue.
Business & M&A
Medytox Escalates Daewoong Damages Claim to ₩500 Billion
South Korea's toxin patent dispute intensifies as Medytox seeks tenfold increase in damages.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Medytox seeks ₩500 billion in damages—a tenfold increase from its original claim.
The dispute centers on proprietary strain development and manufacturing processes—assets worth billions if one party can exclude the other from key markets. Medytox's appeal strategy suggests it believes the initial damages award was insufficient to compensate for lost market opportunity. For practitioners watching the Korean toxin market, the outcome could affect product availability, pricing, and supply chain reliability if either company faces production constraints or licensing restrictions.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.